Key result
Oncohypertension is an emerging clinical entity that addresses the complex bidirectional relationship between cancer and hypertension, including the hypertensive side effects of anti-cancer therapies.
Why the study?
High blood pressure is common in cancer patients and anti-cancer drugs can induce or aggravate hypertension, warranting further investigation into the connection between hypertension and cardiovascular morbidity, mortality, and renal function.
Oncohypertension is an emerging clinical entity that highlights the bidirectional relationship between cancer, antineoplastic therapies, and hypertension, requiring multidisciplinary management.
Answers are grounded in this paper and cite their sources.
Oncohypertension needs prospective study; hypothesis-generating for CV/renal risk in cancer patients.
Implication for health policy/practice/research/medical education: Oncohypertension addressed the connection between cancer and hypertension.High blood pressure is a common comorbidity in cancer patients.Similarly, several anti-cancer drugs can exacerbate the new onset of hypertension or aggravate pre-existing high blood pressure by several mechanisms.Therefore, the connection between hypertension and cardiovascular mortality, morbidity, and renal function requires further investigation.The oncohypertension serve as a new entity among oncologist, nephrologist, and cardiologist.
No takes yet. Share an insight, caveat, or question.
Alem et al. (2023) conducted a review in Oncohypertension (Cancer and Hypertension). Anti-cancer therapies and antihypertensive agents was evaluated. Oncohypertension is an emerging clinical entity that addresses the complex bidirectional relationship between cancer and hypertension, including the hypertensive side effects of anti-cancer therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: